The Principle

Oncocidia works by delivering to tumors a highly targeted (localized) dose of the radioactive chemical Iodine-131.  

Iodine-131 is already a well established cancer drug; it is used to treat thyroid cancer, where it achieves a full remission rate of over 90%. 

Iodine-131 targets the thyroid naturally; the innovation of Oncocidia is to use doses of Iodine-131 to treat other cancers.  

To achieve this, the patient is first injected with a Vascular Disruptive Agent*, which targets tumors present in the body and largely destroys them. 

24 hours later, the patient is given a second injection, of a substance containing radioactive Iodine-131; this substance** targets the partially destroyed tumor and irradiates it at very short range (1-3mm), completing the destruction.

The animal experiments show that Oncocidia targets and destroys both primary and metastatic tumors.

* Combretastatin A4 Phosphate, CA4P.  CA4P, acting alone, fails as a cancer therapy because the tumor     destruction is incomplete and soon reversed.
** Radio-iodinated hypericin, 131-I-Hyp.